当前位置: 首页 >> 检索结果
221. Intracardiac Echocardiography-Guided Implantation for Proximal Left Bundle Branch Pacing.
作者: XiaoHui Kuang.;Xi Zhang.;YanJu Cui.;FeiYu Wei.;Peng Wu.;XiaoLong Gao.;Hong Xiang.;HaiYan Wu.;Li-Lin Wang.;Xiaohong Zhou.;Weijian Huang.;Jie Fan.
来源: Circ Arrhythm Electrophysiol. 2023年16卷4期e011408页
Multiple screw-in attempts under fluoroscopy are often needed to place the pacing lead tip near or at the left bundle branch (LBB). This study was conducted to evaluate the feasibility of implanting an LBB pacing lead in the proximal LBB (PLBB) guided by intracardiac echocardiography (ICE).
222. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
作者: Jung-Kyu Han.;Doyeon Hwang.;Seokhun Yang.;Sang-Hyeon Park.;Jeehoon Kang.;Han-Mo Yang.;Kyung Woo Park.;Hyun-Jae Kang.;Bon-Kwon Koo.;Seung-Ho Hur.;Weon Kim.;Seok Yeon Kim.;Sang-Hyun Park.;Seung Hwan Han.;Sang-Hyun Kim.;Sanghoon Shin.;Yong Hoon Kim.;Kyungil Park.;Namho Lee.;Seung Jin Lee.;Jin Won Kim.;Hyo-Soo Kim.
来源: Circulation. 2023年147卷18期1358-1368页
Limited data are available on short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention using third-generation drug-eluting stents with ultrathin struts and advanced polymer technology. We investigated whether 3- to 6-month DAPT was noninferior to 12-month DAPT after implantation of drug-eluting stents with ultrathin struts and advanced polymer technology.
223. Eliminating Medication Copayments for Low-Income Older Adults at High Cardiovascular Risk: A Randomized Controlled Trial.
作者: David J T Campbell.;Chad Mitchell.;Brenda R Hemmelgarn.;Marcello Tonelli.;Peter Faris.;Jianguo Zhang.;Ross T Tsuyuki.;Jane Fletcher.;Flora Au.;Scott Klarenbach.;Derek V Exner.;Braden J Manns.; .
来源: Circulation. 2023年147卷20期1505-1514页
One in eight people with heart disease has poor medication adherence that, in part, is related to copayment costs. This study tested whether eliminating copayments for high-value medications among low-income older adults at high cardiovascular risk would improve clinical outcomes.
224. Cluster Randomized Trial of a Personalized Clinical Decision Support Intervention to Improve Statin Prescribing in Patients With Atherosclerotic Cardiovascular Disease.
作者: Salim S Virani.;David J Ramsey.;Dax Westerman.;Mark K Kuebeler.;Liang Chen.;Julia M Akeroyd.;Glenn T Gobbel.;Christie M Ballantyne.;Laura A Petersen.;Alexander Turchin.;Michael E Matheny.
来源: Circulation. 2023年147卷18期1411-1413页 225. Effect of Electronic Nudges on Influenza Vaccination Rate in Older Adults With Cardiovascular Disease: Prespecified Analysis of the NUDGE-FLU Trial.
作者: Daniel Modin.;Niklas Dyrby Johansen.;Muthiah Vaduganathan.;Ankeet S Bhatt.;Simin Gharib Lee.;Brian L Claggett.;Erica L Dueger.;Sandrine I Samson.;Matthew M Loiacono.;Lars Køber.;Scott D Solomon.;Pradeesh Sivapalan.;Jens Ulrik Stæhr Jensen.;Cyril Jean-Marie Martel.;Palle Valentiner-Branth.;Tyra Grove Krause.;Tor Biering-Sørensen.
来源: Circulation. 2023年147卷18期1345-1354页
Influenza vaccines have been demonstrated to effectively reduce the incidence of influenza infection and potentially associated risks of cardiovascular events in patients with cardiovascular disease (CVD). Despite strong guideline and public health endorsements, global influenza vaccination rates in patients with CVD are highly variable. This prespecified analysis of NUDGE-FLU (Nationwide Utilization of Danish Government Electronic Letter System for Increasing Influenza Vaccine Uptake) examined the effect of digital behavioral nudges on influenza vaccine uptake based on the presence of CVD.
226. Self-Management Support Using Advertising Principles for Older Adults With Low Income at High Cardiovascular Risk: A Randomized Controlled Trial.
作者: David J T Campbell.;Marcello Tonelli.;Brenda R Hemmelgarn.;Peter Faris.;Jianguo Zhang.;Flora Au.;Ross T Tsuyuki.;Chad Mitchell.;Raj Pannu.;Tavis Campbell.;Noah Ivers.;Jane Fletcher.;Derek V Exner.;Braden J Manns.; .
来源: Circulation. 2023年147卷20期1492-1504页
Self-management education and support (SMES) interventions have modest effects on intermediate outcomes for those at risk of cardiovascular disease, but few studies have measured or demonstrated an effect on clinical end points. Advertising for commercial products is known to influence behavior, but advertising principles are not typically incorporated into SMES design.
227. On-Site Computed Tomography-Derived Fractional Flow Reserve to Guide Management of Patients With Stable Coronary Artery Disease: The TARGET Randomized Trial.
作者: Junjie Yang.;Dongkai Shan.;Xi Wang.;Xiaoqing Sun.;Meihua Shao.;Kan Wang.;Yueying Pan.;Zhiqiang Wang.;U Joseph Schoepf.;Rock H Savage.;Mei Zhang.;Mei Dong.;Lei Xu.;Yujie Zhou.;Xiang Ma.;Xinyang Hu.;Liming Xia.;Hesong Zeng.;Zinuan Liu.;Yundai Chen.
来源: Circulation. 2023年147卷18期1369-1381页
Computed tomography-derived fractional flow reserve (CT-FFR) using on-site machine learning enables identification of both the presence of coronary artery disease and vessel-specific ischemia. However, it is unclear whether on-site CT-FFR improves clinical or economic outcomes when compared with the standard of care in patients with stable coronary artery disease.
228. Integrating Community Health Workers into Community-Based Primary Care Practice Settings to Improve Blood Pressure Control Among South Asian Immigrants in New York City: Results from a Randomized Control Trial.
作者: Nadia S Islam.;Laura C Wyatt.;Shahmir H Ali.;Jennifer M Zanowiak.;Sadia Mohaimin.;Keith Goldfeld.;Priscilla Lopez.;Rashi Kumar.;Susan Beane.;Lorna E Thorpe.;Chau Trinh-Shevrin.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷3期e009321页
Blood pressure (BP) control is suboptimal in minority communities, including Asian populations. We evaluate the feasibility, adoption, and effectiveness of an integrated CHW-led health coaching and practice-level intervention to improve hypertension control among South Asian patients in New York City, Project IMPACT (Integrating Million Hearts for Provider and Community Transformation). The primary outcome was BP control, and secondary outcomes were systolic BP and diastolic BP at 6-month follow-up.
229. Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
作者: Hertzel C Gerstein.;Zhuoru Li.;Chinthanie Ramasundarahettige.;Seungjae Baek.;Kelley R H Branch.;Stefano Del Prato.;Carolyn S P Lam.;Renato D Lopes.;Richard Pratley.;Julio Rosenstock.;Naveed Sattar.
来源: Circulation. 2023年147卷13期1004-1013页
In the AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes) cardiovascular outcomes trial, adding either 4 mg or 6 mg weekly of the glucagon-like peptide-1 receptor agonist efpeglenatide to usual care reduced major adverse cardiovascular events (MACE) in people with type 2 diabetes at high cardiovascular risk. Whether these benefits are dose related remains uncertain.
230. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
作者: Prakriti Gaba.;Michelle L O'Donoghue.;Jeong-Gun Park.;Stephen D Wiviott.;Dan Atar.;Julia F Kuder.;KyungAh Im.;Sabina A Murphy.;Gaetano M De Ferrari.;Zbigniew A Gaciong.;Kalman Toth.;Ioanna Gouni-Berthold.;Jose Lopez-Miranda.;François Schiele.;François Mach.;Jose H Flores-Arredondo.;J Antonio G López.;Mary Elliott-Davey.;Bei Wang.;Maria Laura Monsalvo.;Siddique Abbasi.;Robert P Giugliano.;Marc S Sabatine.
来源: Circulation. 2023年147卷16期1192-1203页
Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with regard to efficacy and safety in the long term remains unknown.
231. Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial.
作者: Kirstine Nørregaard Hansen.;Lisette Okkels Jensen.;Michael Maeng.;Martin Kirk Christensen.;Manijeh Noori.;Johnny Kahlert.;Lars Jakobsen.;Anders Junker.;Phillip Freeman.;Julia Ellert-Gregersen.;Bent Raungaard.;Christian Juhl Terkelsen.;Karsten Tange Veien.;Evald Høj Christiansen.
来源: Circ Cardiovasc Interv. 2023年16卷1期e012332页
Biodegradable polymer drug-eluting stents were developed to improve safety and efficacy outcomes for patients undergoing percutaneous coronary intervention. However, few long-term follow-up efficacy studies are available. The study sought to investigate 5-year results from the SORT OUT VII trial (Scandinavian Organization for Randomized Trials With Clinical Outcome) comparing the biodegradable polymer ultrathin-strut sirolimus-eluting Orsiro stent (O-SES) versus the biodegradable polymer biolimus-eluting Nobori stent (N-BES).
232. Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial.
作者: Robert Shaddy.;Michael Burch.;Paul F Kantor.;Susan Solar-Yohay.;Tania Garito.;Sijia Zhang.;Michele Kocun.;Damien Bonnet.
来源: Circ Heart Fail. 2023年16卷3期e009816页
Sacubitril/valsartan has been approved for the management of heart failure (HF) with reduced ejection fraction in adults. PANORAMA-HF trial (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) investigated its effects on clinical outcomes in pediatric patients with HF.
233. Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?
作者: Satyam Sarma.;James P MacNamara.;Bryce N Balmain.;Christopher M Hearon.;Denis J Wakeham.;Andrew R Tomlinson.;Linda S Hynan.;Tony G Babb.;Benjamin D Levine.
来源: Circulation. 2023年147卷5期378-387页
Exercise intolerance is a defining characteristic of heart failure with preserved ejection fraction (HFpEF). A marked rise in pulmonary capillary wedge pressure (PCWP) during exertion is pathognomonic for HFpEF and is thought to be a key cause of exercise intolerance. If true, acutely lowering PCWP should improve exercise capacity. To test this hypothesis, we evaluated peak exercise capacity with and without nitroglycerin to acutely lower PCWP during exercise in patients with HFpEF.
234. Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes.
作者: Rosalie A Scholtes.;Anne C Hesp.;Charlotte M Mosterd.;Frank Geurts.;Ewout J Hoorn.;Daan J Touw.;Merle M Krebber.;Jaap A Joles.;Hiddo J L Heerspink.;Daniël H van Raalte.
来源: Circulation. 2022年146卷24期1895-1897页 235. BioMatrix Versus Orsiro Stents for Coronary Artery Disease: A Multicenter, Randomized, Open-Label Study.
作者: Chang-Hwan Yoon.;Ju-Seung Kwun.;Young Jin Choi.;Jin Joo Park.;Si-Hyuck Kang.;Sun-Hwa Kim.;Jung-Won Suh.;Tae-Jin Youn.;Myeong-Kon Kim.;Kwang Soo Cha.;Seung-Hwan Lee.;Bum-Kee Hong.;Seung-Woon Rha.;Woong Chol Kang.;Jae-Hwan Lee.;Sang-Hyun Kim.;In-Ho Chae.
来源: Circ Cardiovasc Interv. 2023年16卷1期e012307页
Comparative studies of ultrathin-strut biodegradable polymer sirolimus-eluting stent (BP-SES) have reported promising results and validated its excellent outcomes in terms of safety and efficacy. However, there are limited studies comparing BP drug-eluting stents with struts of different thicknesses. We compared the long-term clinical outcomes of patients treated with an ultrathin-strut BP-SES or a thick-strut biodegradable polymer biolimus-eluting stent (BP-BES).
236. First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).
作者: Bruce S Stambler.;Francis Plat.;Philip T Sager.;Silvia Shardonofsky.;Douglas Wight.;Diane Potvin.;A Shekhar Pandey.;James E Ip.;Benoit Coutu.;Blandine Mondésert.;Laurence D Sterns.;Matthew Bennett.;Jeffrey L Anderson.;Roger Damle.;Ronald Haberman.;A John Camm.
来源: Circ Arrhythm Electrophysiol. 2022年15卷12期e010915页
Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medically supervised intervention. Intranasal etripamil, is an investigational fast-acting, nondihydropyridine, L-type calcium channel blocker, designed for unsupervised self-administration to terminate atrioventricular nodal-dependent PSVT. Phase 2 results showed potential safety and efficacy of etripamil in 104 patients with PSVT.
237. Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants.
作者: Michael V Di Maria.;David J Goldberg.;Victor Zak.;Chenwei Hu.;Adam M Lubert.;Andreea Dragulescu.;Andrew S Mackie.;Andrew McCrary.;Angela Weingarten.;Anitha Parthiban.;Benjamin Goot.;Bryan H Goldstein.;Carolyn Taylor.;Christopher Lindblade.;Christopher J Petit.;Christopher Spurney.;David M Harrild.;Elaine M Urbina.;Eleanor Schuchardt.;Gi Beom Kim.;Ja Kyoung Yoon.;Jamie N Colombo.;Matthew D Files.;Megan Schoessling.;Peter Ermis.;Pierre C Wong.;Ruchira Garg.;Sara K Swanson.;Shaji C Menon.;Shubhika Srivastava.;Thor Thorsson.;Tiffanie R Johnson.;Usha S Krishnan.;Stephen M Paridon.;Peter C Frommelt.; .
来源: Circ Cardiovasc Imaging. 2022年15卷11期e013676页
The FUEL trial (Fontan Udenafil Exercise Longitudinal) demonstrated statistical improvements in exercise capacity following 6 months of treatment with udenafil (87.5 mg po BID). The effect of udenafil on echocardiographic measures of single ventricle function in this cohort has not been studied.
238. Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH.
作者: Xue-Qiao Zhao.;Jie Sun.;Daniel S Hippe.;Daniel A Isquith.;Gador Canton.;Kiyofumi Yamada.;Niranjan Balu.;John R Crouse.;Todd J Anderson.;John Huston.;Kevin D O'Brien.;Thomas S Hatsukami.;Chun Yuan.; .
来源: Circ Cardiovasc Imaging. 2022年15卷11期e014229页
Intraplaque hemorrhage (IPH) is associated with plaque progression and ischemic events, and plaque lipid content (% lipid core) predicts the residual atherosclerotic cardiovascular disease risk. This study examined the impact of IPH on lipid content change in the setting of intensive lipid-lowering therapy.
239. Improvements and Maintenance of Clinical and Functional Measures Among Rural Women: Strong Hearts, Healthy Communities-2. 0 Cluster Randomized Trial.
作者: Rebecca A Seguin-Fowler.;Galen D Eldridge.;Chad D Rethorst.;Meredith L Graham.;Margaret Demment.;David Strogatz.;Sara C Folta.;Jay E Maddock.;Miriam E Nelson.;Seungyeon Ha.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷11期e009333页
Cardiovascular disease is the leading cause of death in the United States; however, women and rural residents face notable health disparities compared with male and urban counterparts. Community-engaged programs hold promise to help address disparities through health behavior change and maintenance, the latter of which is critical to achieving clinical improvements and public health impact.
240. Quality of Life Trajectory and Its Mediators in Older Patients With Acute Decompensated Heart Failure Receiving a Multi-Domain Rehabilitation Intervention: Results From the Rehabilitation Therapy in Older Acute Heart Failure Patients Trial.
作者: David Whellan.;Melissa M McCarey.;Haiying Chen.;M Benjamin Nelson.;Amy M Pastva.;Pamela Duncan.;Robert J Mentz.;Dalane W Kitzman.;Gordon Reeves.;Shelby D Reed.
来源: Circ Heart Fail. 2022年15卷12期e009695页
As patients with heart failure experience worsening of their condition, including acute decompensated heart failure, quality of life deteriorates. However, the trajectory of quality of life changes and their determinants in the context of the Rehabilitation Therapy in Older Acute Heart Failure Patients trial physical rehabilitation intervention are unknown.
|